NANTES, France, March 07, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), announces that it has disclosed its novel bispecific checkpoint inhibitor (BiCKI®) platform in a plenary session at the World Immunotherapy Congress held in San Diego.
"BiCKI® represents a new proprietary multi-specific technology that has the potential to transform the current anti-PD-1 standard of care for hard to treat cancers," said Nicolas Poirier, Ph.D., chief scientific officer of OSE Immunotherapeutics. "Adding to our already strong immuno-oncology pipeline, our new anti-PD-1 bispecifics have the potential to extend the benefits of immunotherapy beyond inflamed tumors in a number of indications by reinstating sustained adaptive and innate immune responses that are naturally inhibited in the tumor microenvironment."
The oral presentation, entitled, “Inactivating Treg cells in tumor microenvironment to improve efficacy of checkpoint inhibitors,” given by Dr. Poirier described a bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) and targeting innovative targets. The BiCKI® platform strives to inhibit key immune checkpoints while simultaneously delivering intratumoral cytokines with Treg modulating function and/or increasing exhausted T cell responses. The BiCKI® platform can also modify the tumor microenvironment by delivering costimulatory signals to rewire anti-tumoral T cell activities or other modalities re-instating, among others, macrophage polarization and phagocytic functions.
Based on an engineered anti-PD-1 bifunctional antibody platform technology, BiCKI® is designed to extend the spectrum of patients responding to immunotherapies. BiCKI® represents the second generation of PD-(L)1 inhibitors that have been used to increase antitumor efficacy in hard to treat cancers by addressing untapped immune evasion mechanisms.
About the World Immunotherapy Congress
The vision of the World Immunotherapy Congress is to bring together the full community and provide a single meeting point for the whole value chain. It is where science meets business to make immunotherapy the cornerstone of the fight against cancer. The Festival of Biologics San Diego was born out of our successful European event, the Festival Of Biologics Basel, which consists of 5 world leading events: The European Antibody Congress, the World Immunotherapy Congress, Clinical Trials 2018, The World Biosimilar Congress and HPAPI World Congress. Having run very successfully in Basel, Switzerland for the past three years, and across other European countries for the past 13 years, it was time to bring the event across the pond to the U.S., where biologics research and development is fast growing and innovative. With high level, global speakers from big pharma, biotech, academia and industry, the Festival of Biologics San Diego will address the strategic and commercial aspects of discovering, developing, and bringing new biologics to patients. The conference brings you two days packed full of top level science, data and case studies, workshops, roundtables and networking opportunities. With 200+ speakers, 80 sponsors and exhibitors and hundreds of companies in attendance, this is not an event to be missed.
About OSE Immunotherapeutics
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company has a diversified first-in-class clinical portfolio consisting of several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. The most advanced therapeutic-candidate, Tedopi®, is a proprietary combination of 10 neo-epitopes aimed at stimulating T-lymphocytes and is currently in Phase 3 development in non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure (anti PD-1 and anti PD-L1) and in Phase 2 testing in pancreatic cancer in combination with checkpoint inhibitor Opdivo®. FR104 (an anti-CD28 mAb) has successfully completed Phase 1 testing and has potential to treat autoimmune diseases. BI 765063 (OSE-172) (anti-SIRPa monoclonal antibody) is under a license and collaboration agreement with Boehringer Ingelheim; this checkpoint inhibitor has received CTA from French and Belgian health authorities for a Phase 1 clinical trial in multiple cancer indications. OSE-127 (monoclonal antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor) is partnered with Servier under an option agreement up to the completion of a Phase 2 clinical trial planned in autoimmune bowel diseases; in parallel, Servier plans a development in the Sjögren syndrome. OSE-127 is currently under Phase 1 clinical trial.
+33 143 297 857
|U.S. Media: LifeSci Public Relations|
Darren Opland, Ph.D.
+1 646 627 8387
|French Media: FP2COM|
+33 607 768 283
|U.S. and European Investors|
+41 79 367 6254
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import.
Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance.
This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 26 April 2018, including the annual financial report for the fiscal year 2017, available on the OSE Immunotherapeutics’ website.
Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.